Effect of insulin glargine on endogenous insulin secretion and beta-cell function in Japanese type 2 diabetic patients using oral antidiabetic drugs

Endocrine Journal

Volumn 61, Issue 1, 2014, Pages 13-18

  Ohta, Akio ^a   Kato, Hiroyuki ^a   Murayama, Katura ^a   Hashimoto, Eriko ^a   Murakami, Mariko ^a   Nishine, Ami ^a   Ohshige, Toshihiko ^a   Sada, Yoshiyuki ^a   Asai, Shiko ^a   Kawata, Takehiro ^a   Nagai, Yoshio ^a   Katabami, Takuyuki ^a   Tanaka, Yasushi ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Free fatty acids; Insulin glargine; Proinsulin c peptide ratio; Type 2 diabetes

Indexed keywords

C PEPTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; PROINSULIN; SULFONYLUREA;

AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; DRUG DOSE TITRATION; DRUG EFFECT; ENDOCRINE FUNCTION TEST; FASTING PLASMA GLUCOSE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN RELEASE; JAPANESE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PROTEIN BLOOD LEVEL; TEST MEAL;

AGED; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, LONG-ACTING; INSULIN-SECRETING CELLS; JAPAN; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; SULFONYLUREA COMPOUNDS;

EID: 84893389056     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ13-0304     Document Type: Article

References (18)

1. Kahn SE (2003) The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 46: 3-19.
2. Fukushima M, Usami M, Ikeda M, et al. (2004) Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross-sectional study of Japanese type 2 diabetes. Metabolism 53: 831-835.
3. Tanaka Y, Atsumi Y, Asahina, et al. (1998) Usefulness of Revised Fasting Plasma Glucose Criterion and Characteristics of the Insulin Response to an Oral Glucose Load in Newly Diagnosed Japanese Diabetic Subjects. Diabetes Care 21: 1133-1137.
4. Janka HU, Hessel F, Walzer S, et al. (2007) Insulin glargine added to therapy with oral antidiabetic agents improves glycemic control and reduces long-term complications in patients with type 2 diabetes - a simulation with the Diabetes Mellitus Model (DMM). Int J Clin Pharmacol Ther 45: 623-630.
5. Porcellati F, Bolli GB, Fanelli CG (2011) Pharmacokinetics and pharmacodynamics of basal insulins. Diabetes Technol Ther 13: Suppl 1: S15-24.
6. Odawara M, Ohtani T, Kadowaki T (2012) Dosing of insulin glargine to achieve the treatment target in Japanese type 2 diabetes on a basal supported oral therapy regimen in real life: ALOHA study subanalysis. Diabetes Technol Ther 14: 635-643.
7. Kadowaki T, Ohtani T, Odawara M (2012) Potential formula for the calculation of starting and incremental insulin glargine doses: ALOHA subanalysis. PLoS One 7: e41358.
8. Pennartz C, Schenker N, Menge BA, et al. (2011) Chronic reduction of fasting glycemia with insulin glargine improves first- and second-phase insulin secretion in patients with type 2 diabetes. Diabetes Care 34: 2048-2053.
9. Pistrosch F, Köhler C, Schaper F, et al. (2013) Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes. Acta Diabetol [Epub ahead of print]
10. Forst T, Larbig M, Hohberg C, et al. (2010) Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial beta-cell protection in individuals with type 2 diabetes. Diabetes Obes Metab 12: 437-441.
11. Roden M, Price TB, Perseghin G, et al. (1996) Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 97: 2859-2865.
12. Paolisso G, Howard BV (1998) Role of non-esterified fatty acids in the pathogenesis of type 2 diabetes mellitus. Diabet Med 15: 360-366.
13. Samuel VT, Petersen KF, Shulman GI (2010) Lipidinduced insulin resistance: unravelling the mechanism. Lancet 375: 2267-2277.
14. Bajaj M, Berria R, Pratipanawatr T, et al. (2002) Free fatty acid-induced peripheral insulin resistance augments splanchnic glucose uptake in healthy humans. Am J Physiol Endocrinol Metab 283: 346-352.
15. Bunck MC, Cornér A, Eliasson B, et al. (2010) Oneyear treatment with exenatide vs. insulin glargine: Effects on postprandial glycemia, lipid profiles, and oxidative stress. Atherosclerosis 212: 223-229.
16. Jovanovic A, Gerrard J, Taylor R (2009) The secondmeal phenomenon in type 2 diabetes. Diabetes Care 32: 1199-1201.
17. ORIGIN Trial Investigators (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367: 319-328.
18. Takahara M, Shiraiwa T, Kaneto H, et al. (2012) Efficacy of sitagliptin on blood glucose fluctuation in Japanese type 2 diabetic patients with basal-supported oral therapy. Endocr J 59: 1131-1136.